The study showed telmisartan was as effective as ramipril but with lower rates of cough and angioedema, which led to fewer discontinuations.
The Prevention Regimen For Effectively Avoiding Second Strokes (PRoFESS) study investigated therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years.